# A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection

> **NCT02532283** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 102 (actual)

## Conditions studied

- Influenza A Virus

## Interventions

- **DRUG:** JNJ-63623872
- **DRUG:** Placebo
- **DRUG:** Oseltamivir

## Key facts

- **NCT ID:** NCT02532283
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-12-11
- **Primary completion:** 2017-02-24
- **Final completion:** 2017-03-15
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2020-03-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02532283

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02532283, "A Study to Evaluate the Pharmacokinetics, Safety, and Antiviral Activity of JNJ-63623872 in Combination With Oseltamivir in Adult, and Elderly Hospitalized Participants With Influenza A Infection". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02532283. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*